Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease

被引:0
|
作者
K G Claridge
R Ghabrial
G Davis
M Tomlinson
S Goodman
R A Harrad
M J Potts
机构
[1] Bristol Eye Hospital,
[2] United Bristol Hospital Trust,undefined
[3] Bristol Oncology Centre,undefined
[4] United Bristol Hospital Trust,undefined
来源
Eye | 1997年 / 11卷
关键词
Thyroid eye disease; Graves' ophthalmopathy; Orbital radiation; Azathioprine; Immunosuppression;
D O I
暂无
中图分类号
学科分类号
摘要
Although systemic steroids or orbital radiotherapy are effective in limiting the inflammatory response in thyroid eye disease (TED), there are reports of over 70% of treated patients requiring subsequent rehabilitative surgery: either orbital decompression or strabismus correction. This study investigated whether combined immunosuppression with primary orbital radiotherapy together with azathioprine and low-dose prednisolone, applied early in the active disease state, was more effective in treating TED. Forty consecutive patients with active TED were recruited. Orbital MRI (STIR sequence) was used to assess disease activity. Median duration of symptoms was 1.0 year. Subjects were treated with bilateral orbital radiotherapy (20 Gy in 10 fractions) and oral prednisolone and azathioprine. Pre- and post-treatment activity was measured clinically, including uniocular field of fixation, Mourits score and total eye score, until TED became inactive off all treatment. Before treatment, 15 subjects had signs of dysthyroid optic neuropathy, 35 had significant motility restriction and 38 had marked soft tissue signs. On average TED became inactive after 1.2 years (SD 0.7) of immunosuppression, and treatment was well tolerated. One patient required subsequent cosmetic orbital decompression, 6 had successful strabismus surgery and 13 required minor cosmetic lid surgery. Compared with previously reported treatment regimes we think that combined orbital radiotherapy and medical immunosuppression is far more effective than either treatment alone in the management of active TED, and led to fewer side effects of high-dose steroids. In particular there was more than a four-fold reduction in the requirement for orbital decompression and strabismus surgery.
引用
收藏
页码:717 / 722
页数:5
相关论文
共 50 条
  • [21] Management of strabismus in thyroid eye disease
    Harrad, R.
    EYE, 2015, 29 (02) : 234 - 237
  • [22] Diagnosis and management of thyroid eye disease
    Denniston, A
    Dodson, P
    Reuser, T
    HOSPITAL MEDICINE, 2002, 63 (03): : 152 - 156
  • [23] MANAGEMENT OF EYE MANIFESTATIONS OF THYROID DISEASE
    MCDOUGALL, IR
    KRISS, JP
    PHARMACOLOGY & THERAPEUTICS PART C-CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1977, 2 (01): : 95 - 111
  • [24] Current Management of Thyroid Eye Disease
    Mahoney, Nicholas R.
    Rajaii, Fatemeh
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2021, 23 (07)
  • [25] Management of strabismus in thyroid eye disease
    R Harrad
    Eye, 2015, 29 : 234 - 237
  • [26] Management of patients with thyroid eye disease
    Karra, Efthimia
    Yousseif, Ahmed
    Rose, Geoffrey E.
    Baldeweg, Stephanie E.
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2016, 77 (01) : C6 - +
  • [27] Conservative Management of Thyroid Eye Disease
    Khan, Sadaf Humayun
    Malik, Uzma
    Ahmed, Farooq
    Siddiqui, Zahid Kamal
    Munir, Samavia
    Rashid, Nawaz
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (05): : 599 - 601
  • [28] Current Management of Thyroid Eye Disease
    Nicholas R. Mahoney
    Fatemeh Rajaii
    Current Treatment Options in Neurology, 2021, 23
  • [29] Update on thyroid eye disease and management
    Bothun, Erick D.
    Scheurer, Ryan A.
    Harrison, Andrew R.
    Lee, Michael S.
    CLINICAL OPHTHALMOLOGY, 2009, 3 : 543 - 551
  • [30] Secondary malignancy following radiotherapy for thyroid eye disease
    Gillis, Christopher C.
    Chang, Eun Hae
    Al-Kharazi, Khalid
    Pickles, Tom
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2016, 21 (03) : 156 - 161